With the first-ever human data on the efficacy and safety of aldehyde-trapping in hand from a phase IIa trial against allergic conjunctivitis (AC), Aldeyra Therapeutics Inc. said it will wait to consult U.S. regulators until the next quarter when outcomes from another study testing the same compound, NS2, in non-infectious anterior uveitis (AU) become available.